Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-868-0 | CAS number: 111-42-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
DEA formulated in ethanol showed no oncogenic potential in the rat after unoccluded daily dermal exposure for 2 years. In the dermal mouse carcinogenicity study there was an increased incidence of liver neoplasms in males and females at all doses tested and increased incidences of renal tubule adenomas in males at the high dose level only. Mechanistic research specifically on DEA indicates that, to the extent DEA can potentially induce tumours in mice, it does so by a mechanism that is not relevant to humans. Therefore, based on the available data, DEA is not considered carcinogenic for humans.
Key value for chemical safety assessment
Justification for classification or non-classification
Based on the available data, DEA does not need to be classified for carcinogenicity according to Annex I of Directive 67/548/EEC and according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Additional information
In rats, ethanolic DEA solutions were dermally applied to 50 male and 50 female F344 rats at dose levels of 0, 16, 32, 64 mg/kg bw/day in males or 0, 8, 16, 32 mg/kg bw/day in females for 5 days per week during a period of 103 weeks. The survival of dosed male and female rats was not affected. Mean body weights of the high dose males (64 mg/kg bw/day) were less than those of the vehicle controls during weeks 8 – 89, while the top dose females (32 mg/kg bw/day) revealed body weight reductions after week 97. DEA led to skin irritation (acanthosis, hyperkeratosis, exudation) predominantly at doses of 32 mg/kg bw/day and above at the site of application. In the kidney the incidences and severities of nephropathy in dosed female groups were significantly greater than those in the vehicle controls, DEA was not carcinogenic in this study and the NOAEL for local irritation was 16 mg/kg bw/day and 32 mg/kg bw/day for systemic toxicity in males. In females the LOAEL was 8 mg/kg bw/day for local irritation and systemic toxicity (National Toxicology Program, 1999).
In the mouse oncogenicity study (B6C3F1), the test conditions were similar. Fifty animals per dose group and gender received topically ethanolic DEA solutions of 0, 40, 80 and 160 mg/kg bw/day, 5 times/week for 103 weeks. Survival of dosed female mice was reduced (44/50, 33/50, 33/50; 23/50 for the control, low-, mid- and high-dose groups, respectively). This was attributed to liver neoplasms observed, while there was no effect on survival in males. The mean body weights of the mid/high-dose males were lower at ≥ weeks 88/77, respectively. The mean body weights of the low- and mid-dose females were reduced from week 73 onwards, those of the high-dose females at ≥ week 53. In male mice, the incidences of hepatocellular adenoma and of hepatocellular adenoma and carcinoma (combined) were significantly increased in all dosed groups, while the incidences of hepatoblastoma showed an increase in the mid- and high-dose groups. In the female mice, the incidences of hepatocellular neoplasms were significantly higher in all treated groups compared to the control. Non-neoplastic lesions were seen only in the liver of all dosed male and female mice and consisted of cytoplasmic alteration, characterized by mild to moderate enlargement of centrilobular hepatocytes, and syncytial alteration, characterized by scattered hepatocytes with three or more small nuclei. The incidences of renal tubule adenoma in males occurred with a positive trend; but the incidences of carcinoma and hyperplasia did not follow this pattern. An extended evaluation of kidney step sections revealed additional adenomas and hyperplasias in all dosed groups. The combined analysis of single and step sections indicated a dose-related increase in the incidences of renal tubule hyperplasia and renal tubule adenoma or carcinoma (combined), and an increase in the incidences of renal tubule adenoma in male mice. Incidences of thyroid gland follicular cell hyperplasia were increased in dosed male and female mice compared to vehicle controls. Hyperkeratosis, acanthosis, and exudate were treatment-related changes in the skin at the site of application and the LOAEL for local and systemic effects was 40 mg/kg bw/day (National Toxicology Program, 1999).
The liver tumours in mice in the NTP study (1999) were considered to be directly related to the observed increase in the cellular proliferation rate, which is due to the observed enzyme induction, weak peroxisome proliferation and choline depletion with subsequent disturbance of its metabolism. While nitrosamine formation has been highlighted as a matter of concern for DEA, and for this reason it has been banned for use in cosmetics in the EU, nitrosamine formation was ruled out under the conditions of this study. Benign kidney tumours (adenomas) were only observed in male mice at the high dose level at a low incidence, when using serial sections. Based on the increased S-phase synthesis observed in this organ, it is conceivable that a similar non-genotoxic mode of action involving choline deficiency is responsible for the renal tubular adenomas.
In short term tests on carcinogenicity, DEA was not carcinogenic, when tested in the Tg.AC transgenic mouse model up to topical dose levels exceeding the MTD (Spalding et al, 2000).
Various mechanistic in vitro and in vivo studies identified that DEA induced choline depletion is the key event in the toxic mode of action. The major results are summarised briefly in this section, the studies are described in detail in section 7.9.3.
DEA decreased gap junctional intracellular communication in primary cultured mouse and rat hepatocytes, but all these events were prevented with choline supplementation. DNA hypomethylation was observed in mouse hepatocytes as a further epigenetic mechanism involved in liver tumourigenesis.
DEA decreased phosphatidylcholine synthesis by blocking the cellular uptake of choline in vitro, but these events did not occur in the presence of excess choline.
DEA increased S-phase DNA synthesis in mouse hepatocytes but had no effect on apoptosis. No such effects were noted in human hepatocytesin vitro. Apparent differences in the susceptibility of two different mice strains (B6C3F1 > C57BL) were noted. B6C3F1 mice are extremely sensitive to non-genotoxic effects and are known to possess a relatively high incidence of spontaneous liver tumours. Moreover, chronic stimulation and compensatory adaptive changes of hepatocyte hypertrophy and proliferation are able to enhance the incidence of common spontaneous liver tumours in the mouse by mechanisms not relevant to humans.
Analysis of gene expressions in animal studies showed an increase in genes associated with cell proliferation, while a decrease in genetic processes relevant for apoptotic mechanisms was observed.
In conclusion, mechanistic research specifically on DEA indicates that, to the extent DEA can potentially induce tumours in mice, it does so by a mechanism that is not relevant to humans. Therefore, based on the available data, DEA is not considered carcinogenic for humans.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.